These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 12079194)

  • 1. Constrained four parameter logistic model.
    Altan S; Manola A; Davidian M; Raghavarao D
    Dev Biol (Basel); 2002; 107():71-6. PubMed ID: 12079194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of the four-parameter logistic model to bioassay: comparison with slope ratio and parallel line models.
    Vølund A
    Biometrics; 1978 Sep; 34(3):357-65. PubMed ID: 719119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statistical aspects of design and validation of microtitre-plate-based linear and non-linear parallel in vitro bioassays.
    Zimmermann H; Gerhard D; Dingermann T; Hothorn LA
    Biotechnol J; 2010 Jan; 5(1):62-74. PubMed ID: 19844917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strip-plot designs, mixed models, and comparisons between linear and non-linear models for microtitre plate bioassays.
    Lansky D
    Dev Biol (Basel); 2002; 107():11-23. PubMed ID: 12079185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case study: development of a bioassay for IL-1ra.
    Wolf J
    Dev Biol (Basel); 2002; 107():63-7. PubMed ID: 12079193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Equivalence testing for parallelism in the four-parameter logistic model.
    Jonkman JN; Sidik K
    J Biopharm Stat; 2009 Sep; 19(5):818-37. PubMed ID: 20183446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Latin square vs twin crossover design for mouse blood glucose assay to estimate insulin potency].
    Lin ZG; Zhou HJ
    Zhongguo Yao Li Xue Bao; 1990 Sep; 11(5):454-7. PubMed ID: 2130603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The statistical performance of an MCF-7 cell culture assay evaluated using generalized linear mixed models and a score test.
    Rey deCastro B; Neuberg D
    Stat Med; 2007 May; 26(12):2501-18. PubMed ID: 17109375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bayesian ranking of sites for engineering safety improvements: decision parameter, treatability concept, statistical criterion, and spatial dependence.
    Miaou SP; Song JJ
    Accid Anal Prev; 2005 Jul; 37(4):699-720. PubMed ID: 15949462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Statistical analysis of community-based studies -- presentation and comparison of possible solutions with reference to statistical meta-analytic methods].
    Twardella D; Bruckner T; Blettner M
    Gesundheitswesen; 2005 Jan; 67(1):48-55. PubMed ID: 15672306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Setting specifications for potency assays--basic principles.
    Mire-Sluis AR
    Dev Biol (Basel); 2002; 107():107-15. PubMed ID: 12079184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parameters of a dose-response model are on the boundary: what happens with BMDL?
    Kopylev L; Fox J
    Risk Anal; 2009 Jan; 29(1):18-25. PubMed ID: 18808395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probabilistic dose-response modeling: case study using dichloromethane PBPK model results.
    Marino DJ; Starr TB
    Regul Toxicol Pharmacol; 2007 Dec; 49(3):285-300. PubMed ID: 17949874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the performance of logistic regression model types on growth/no growth data of Listeria monocytogenes.
    Gysemans KP; Bernaerts K; Vermeulen A; Geeraerd AH; Debevere J; Devlieghere F; Van Impe JF
    Int J Food Microbiol; 2007 Mar; 114(3):316-31. PubMed ID: 17239980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support.
    Shen M; Schilder RJ; Obasaju C; Gallo JM
    Cancer Chemother Pharmacol; 2002 Sep; 50(3):243-50. PubMed ID: 12203107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update of potency factors for asbestos-related lung cancer and mesothelioma.
    Berman DW; Crump KS
    Crit Rev Toxicol; 2008; 38 Suppl 1():1-47. PubMed ID: 18671157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement dependent cytotoxicity (CDC) activity of a humanized anti Lewis-Y antibody: FACS-based assay versus the 'classical' radioactive method -- qualification, comparison and application of the FACS-based approach.
    Nechansky A; Szolar OH; Siegl P; Zinoecker I; Halanek N; Wiederkum S; Kircheis R
    J Pharm Biomed Anal; 2009 May; 49(4):1014-20. PubMed ID: 19250790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mixed-effects statistical model for comparative LC-MS proteomics studies.
    Daly DS; Anderson KK; Panisko EA; Purvine SO; Fang R; Monroe ME; Baker SE
    J Proteome Res; 2008 Mar; 7(3):1209-17. PubMed ID: 18251496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model averaging using the Kullback information criterion in estimating effective doses for microbial infection and illness.
    Moon H; Kim HJ; Chen JJ; Kodell RL
    Risk Anal; 2005 Oct; 25(5):1147-59. PubMed ID: 16297221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimation of infection prevalence from correlated binomial samples.
    Condon J; Kelly G; Bradshaw B; Leonard N
    Prev Vet Med; 2004 Jun; 64(1):1-14. PubMed ID: 15219965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.